| Identification | Back Directory | [Name]
N'-dodecanoyl-1-ethyl-4-hydroxy-2-oxo-1,2-dihydroquinoline-3-carbohydrazide | [CAS]
331963-27-0 | [Synonyms]
CP0.7
N'-dodecanoyl-1-ethyl-4-hydroxy-2-oxo-1,2-dihydroquinoline-3-carbohydrazide | [Molecular Formula]
C24H35N3O4 | [MOL File]
331963-27-0.mol | [Molecular Weight]
429.55 |
| Chemical Properties | Back Directory | [Boiling point ]
615.0±55.0 °C(Predicted) | [density ]
1.144±0.06 g/cm3(Predicted) | [form ]
Solid | [pka]
4.50±1.00(Predicted) | [color ]
Off-white to light yellow |
| Hazard Information | Back Directory | [Description]
VP07 is a mitophagy inducer that induces Parkin-dependent mitophagy. | [Uses]
GSK3-IN-3 is a mitophagy inducer, inducing Parkin-dependent mitophagy. GSK3-IN-3 is also a GSK-3 inhibitor with an IC50 value of 3.01 μM. GSK3-IN-3 is non-ATP nor substrate competitive and is neuroprotective against 6-OHDA[1][2][3]. | [References]
[1] Maestro I, et al. Phenotypic Assay Leads to Discovery of Mitophagy Inducers with Therapeutic Potential for Parkinson's Disease. ACS Chem Neurosci. 2021 Dec 15;12(24):4512-4523. DOI:10.1021/acschemneuro.1c00529
[2] Morales-García JA, et al. Glycogen synthase kinase-3 inhibitors as potent therapeutic agents for the treatment of Parkinson disease. ACS Chem Neurosci. 2013 Feb 20;4(2):350-60. DOI:10.1021/cn300182g
[3] Palomo V, et al. Exploring the binding sites of glycogen synthase kinase 3. Identification and characterization of allosteric modulation cavities. J Med Chem. 2011 Dec 22;54(24):8461-70. DOI:10.1021/jm200996g |
|
| Company Name: |
Specs
|
| Tel: |
+31 15 251 8111 |
| Website: |
www.specs.net |
|